Financing ·
Immuron reduces ATM offering capacity to $2.0M under H.C. Wainwright agreement
IMRNImmuron Ltd
Immuron Limited has amended its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to decrease the aggregate maximum offering price of American Depositary Shares available for sale from approximately $4.85 million to $2,006,769. This adjustment was made pursuant to General Instruction I.B.5 of Form F-3, which excludes securities previously sold during the 12-calendar month period ending October 23, 2026. The company filed a Current Prospectus Supplement to reflect this reduction in available capital under its existing shelf registration statement. Immuron Limited is an Australian biotechnology company focused on developing immunotherapies for cancer.